18:20 , Aug 31, 2018 |  BC Week In Review  |  Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016 deal,...
21:00 , Aug 22, 2018 |  BC Extra  |  Company News

AbbVie exercises option for argenx cancer candidate

AbbVie Inc. (NYSE:ABBV) exercised an option for exclusive, worldwide rights to develop and commercialize ARGX-115 from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX). argenx told BioCentury it has received $60 million from AbbVie thus far under the 2016...
19:15 , Jul 6, 2017 |  BioCentury  |  Emerging Company Profile

LAPping up TGF beta

Tilos Therapeutics Inc. aims to boost antitumor immunity by blocking TGF beta-induced production of immunosuppressive cells. By arresting TGF beta in its immature, inactive form, the company’s antibodies could be more effective than therapies that...
07:00 , Apr 25, 2016 |  BC Week In Review  |  Company News

argenx, AbbVie deal

AbbVie acquired an exclusive option from argenx to license ARGX-115, a mAb against leucine-rich repeat containing 32 ( LRRC32; GARP) that is in preclinical testing to treat cancer. argenx will be responsible...
03:07 , Apr 22, 2016 |  BC Extra  |  Company News

AbbVie gets option for argenx mAb

AbbVie Inc. (NYSE:ABBV) acquired an exclusive option from argenx N.V. (Euronext:ARGX) to license ARGX-115, a preclinical mAb against leucine-rich repeat containing 32 ( LRRC32; GARP), to treat cancer. argenx will be responsible for R&D through...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Universite catholique de Louvain, arGEN-X deal

arGEN-X exercised an exclusive option to license worldwide rights to a preclinical mAb against leucine-rich repeat containing 32 ( LRRC32; GARP) from the de Duve Institute at the university. arGEN-X said the institute...